APOGEPHA International

With the development of a drug for the treatment of urinary incontinence (active ingredient: propiverine), APOGEPHA is one of the most important companies in the global market for urological spasmolytics.

[Translate to English:] Zwei Mitarbeiter von APOGEPHA lächeln freundlich.

APOGEPHA: important player in the field of urology

APOGEPHA is an independent, German, medium-sized pharmaceutical company.

We have developed propiverine, one of the leading medicines for the treatment of overactive bladder and neurogenic detrusor overactivity in adults and children. The drug is currently available in over 25 countries worldwide.

Various dosages and formulations of propiverine are available under the brand names Mictonorm®, Mictoryl® and Detrunorm®.

The unique, once-dailypropiverine formulation Mictonorm Uno® is also approved in most countries. We currently have marketing and sales partners in over 25 countries, with a focus on Europe and Asia.

We are looking for out-licensing partners with expertise in the field of urology in all promising markets.

Login

Login for sales partners to receive detailed information and material:

Login Here

Countries and products

[Translate to English:] Interaktive Grafik zeigt, in welchen Ländern weltweit APOGEPHA Produkte auf dem Markt bzw. unter Vertrag hat und wo eine Markteinführung bevorsteht.